Patient with and without diabetes who received patiromer were more likely to remain on spironolactone at 12 weeks compared with those who received placebo, a subgroup analysis of the AMBER trial showed.
How much do your patients know about the dangers of high potassium levels in the body? They may know that potassium is good for you, or that you need specific levels of it in the blood, but they may not know the effects of high potassium, or hyperkalemia. As their healthcare professional, how can you educate them on the dangers of hyperkalemia?
Investigators reviewed 13 trials of spironolactone and 1 trial of eplerenone.
Appropriate treatment for hyperkalemia might be a key factor to improving renal outcome in patients with CKD, according to investigators.
Even a single episode of hyperkalemia is associated with a major disease burden, a study finds.
Nearly two-thirds of inpatients with a hyperkalemia diagnosis do not receive potassium binders, according to a contemporary analysis.
Nearly 74% of hemodialysis patients experienced pre-dialysis hyperkalemia within 1 year of enrollment in the Dialysis Outcomes and Practice Patterns Study, according to investigators.
Study findings support the potential clinical utility of laxatives for hyperkalemia management in patients with nondialysis-dependent CKD.
Modifying the potassium concentration used for dialysis may decrease mortality risk among hospitalized patients with end-stage kidney disease and severe hyperkalemia, according to investigators.
In a study, patients who experienced hyperkalemia while on a renin-angiotensin-aldosterone-system inhibitor had the lowest 1-year risk of recurrent hyperkalemia when the medication was discontinued.
